Join our daily newsletter At The Bell to receive exclusive market insights
- AdAlta (1AD) has been granted a patent for its lead product AD-214 by the China National Intellectual Property Administration
- The new patent protects the i-body sequence used in AD-214 and pharmaceutical compositions and diagnostic applications containing similar i-body sequences
- The patent, which expires on January 8, 2036, also protects the use of the sequences in therapeutic and diagnostic applications including idiopathic pulmonary fibrosis
- AdAlta says it is looking to file patent applications in other major markets including the European Union and India
- 1AD shares steady at 75 cents
Clinical-stage biotech company AdAlta (1AD) has clinched a Chinese patent approval for its lead product AD-214 from the China National Intellectual Property Administration.
The company said the new patent protects the i-body sequence used in AD-214 and pharmaceutical compositions and derivatives containing similar i-body sequences.
It also protects the use of the sequences in therapeutic and diagnostic applications including idiopathic pulmonary fibrosis (IPF).
AD-214 is being developed for the treatment of IPF and other human fibrotic diseases.
The patent entitled “CXCR4 binding molecules” expires on January 8, 2036.
AdAlta said China was the fifth country to grant AD-214’s patent protection.
“China is now the second largest (and fastest growing) pharmaceutical market in the world (after the US), representing 11 per cent of the global prescription drug market,” Managing Director and CEO Dr Tim Oldham said.
“IPF is included in the Chinese rare diseases list, including it as part of China’s plan to increase availability of drugs for rare diseases.
“Patent protection for AD-214 in this important market is anticipated to further increase the already significant interest from potential China partners.”
AdAlta said it intended filing patent applications in other major markets such as the European Union and India after securing patent approvals in Australia, the US, Japan, Singapore and now China.
The i-body technology platform mimics the shape and stability of a unique and versatile antigen-binding domain, which results in proteins that can interact with previously difficult-to-access targets implicated in many serious diseases.
The company has completed phase-one clinical studies for the lead i-body candidate AD-214.
1AD shares were steady at 7.5 cents at 11:45 am AEDT.
